Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics
Foundation Medicine announced plans to launch two new germline tests in the United States through a partnership with Fulgent Genetics (NASDAQ: FLGT). The tests, FoundationOne®Germline and FoundationOne®Germline More, will be available from February 28, 2025, and can be added to any Foundation Medicine comprehensive genomic profiling test.
FoundationOne®Germline analyzes 50 genes associated with hereditary cancers, while FoundationOne®Germline More is an expanded panel analyzing 154 genes. Both tests use Fulgent's proprietary technology platform to analyze single nucleotide and copy number variations. When combined with Foundation Medicine's existing tests, they help healthcare providers build comprehensive molecular profiles for cancer patients, explaining cancer development and potential future cancer risks.
Foundation Medicine ha annunciato piani per lanciare due nuovi test germline negli Stati Uniti attraverso una partnership con Fulgent Genetics (NASDAQ: FLGT). I test, FoundationOne®Germline e FoundationOne®Germline More, saranno disponibili dal 28 febbraio 2025 e possono essere aggiunti a qualsiasi test di profilazione genomica completa di Foundation Medicine.
FoundationOne®Germline analizza 50 geni associati a cancri ereditari, mentre FoundationOne®Germline More è un pannello ampliato che analizza 154 geni. Entrambi i test utilizzano la piattaforma tecnologica proprietaria di Fulgent per analizzare variazioni a singolo nucleotide e variazioni nel numero di copie. Quando combinati con i test esistenti di Foundation Medicine, aiutano i fornitori di assistenza sanitaria a costruire profili molecolari completi per i pazienti affetti da cancro, spiegando lo sviluppo del cancro e i potenziali futuri rischi di cancro.
Foundation Medicine anunció planes para lanzar dos nuevas pruebas germinales en los Estados Unidos a través de una asociación con Fulgent Genetics (NASDAQ: FLGT). Las pruebas, FoundationOne®Germline y FoundationOne®Germline More, estarán disponibles a partir del 28 de febrero de 2025 y se pueden agregar a cualquiera de las pruebas de perfil genómico integral de Foundation Medicine.
FoundationOne®Germline analiza 50 genes asociados con cánceres hereditarios, mientras que FoundationOne®Germline More es un panel ampliado que analiza 154 genes. Ambas pruebas utilizan la plataforma tecnológica propietaria de Fulgent para analizar variaciones de nucleótidos simples y variaciones en el número de copias. Cuando se combinan con las pruebas existentes de Foundation Medicine, ayudan a los proveedores de atención médica a construir perfiles moleculares completos para pacientes con cáncer, explicando el desarrollo del cáncer y los posibles riesgos futuros de cáncer.
파운데이션 메디슨이 풀젠트 제네틱스 (NASDAQ: FLGT)와의 파트너십을 통해 미국에서 두 가지 새로운 유전 검사를 출시할 계획을 발표했습니다. FoundationOne®Germline과 FoundationOne®Germline More라는 이 검사는 2025년 2월 28일부터 이용 가능하며, 모든 파운데이션 메디슨의 종합 유전체 프로파일링 검사에 추가할 수 있습니다.
FoundationOne®Germline은 유전성 암과 관련된 50개의 유전자를 분석하고, FoundationOne®Germline More는 154개의 유전자를 분석하는 확장된 패널입니다. 두 검사는 풀젠트의 독점 기술 플랫폼을 사용하여 단일 뉴클레오타이드 변이와 복제 수 변이를 분석합니다. 기존의 파운데이션 메디슨 검사를 결합할 때, 암 환자를 위한 포괄적인 분자 프로파일을 구축하는 데 도움을 주어 암의 발달과 향후 암 위험을 설명합니다.
Foundation Medicine a annoncé son intention de lancer deux nouveaux tests germinaux aux États-Unis grâce à un partenariat avec Fulgent Genetics (NASDAQ: FLGT). Les tests, FoundationOne®Germline et FoundationOne®Germline More, seront disponibles à partir du 28 février 2025 et pourront être ajoutés à tout test de profilage génomique complet de Foundation Medicine.
FoundationOne®Germline analyse 50 gènes associés aux cancers héréditaires, tandis que FoundationOne®Germline More est un panel élargi qui analyse 154 gènes. Les deux tests utilisent la plateforme technologique propriétaire de Fulgent pour analyser des variations de nucléotides simples et des variations du nombre de copies. Lorsqu'ils sont combinés avec les tests existants de Foundation Medicine, ils aident les prestataires de soins de santé à établir des profils moléculaires complets pour les patients atteints de cancer, expliquant le développement du cancer et les risques potentiels futurs de cancer.
Foundation Medicine hat Pläne angekündigt, zwei neue Keimbahn-Tests in den Vereinigten Staaten in Zusammenarbeit mit Fulgent Genetics (NASDAQ: FLGT) einzuführen. Die Tests, FoundationOne®Germline und FoundationOne®Germline More, werden ab dem 28. Februar 2025 verfügbar sein und können zu jedem umfassenden genomischen Profiling-Test von Foundation Medicine hinzugefügt werden.
FoundationOne®Germline analysiert 50 Gene, die mit erblichen Krebserkrankungen in Verbindung stehen, während FoundationOne®Germline More ein erweitertes Panel ist, das 154 Gene analysiert. Beide Tests nutzen die proprietäre Technologieplattform von Fulgent, um Einzel-Nukleotid- und Kopienzahlenvariationen zu analysieren. In Kombination mit den bestehenden Tests von Foundation Medicine helfen sie Gesundheitsdienstleistern, umfassende molekulare Profile für Krebspatienten zu erstellen, um die Krebsentwicklung und potenzielle zukünftige Krebsrisiken zu erklären.
- Strategic partnership with Foundation Medicine expands Fulgent's market reach in cancer diagnostics
- Launch of two new genetic testing products diversifies revenue streams
- Integration with Foundation Medicine's comprehensive genomic profiling tests creates cross-selling opportunities
- Product launch not until February 2025, indicating delayed revenue impact
- Enters competitive market with established players in cancer diagnostics
Insights
This strategic partnership marks a significant business expansion for Fulgent Genetics into the high-growth hereditary cancer testing market. The collaboration with Foundation Medicine, a leader in comprehensive genomic profiling, creates multiple value streams:
- Immediate access to Foundation Medicine's established oncology network and integration with their test ordering portal, accelerating market penetration
- Revenue diversification through two distinct test offerings - the focused 50-gene panel and comprehensive 154-gene panel, addressing different clinical needs and price points
- Enhanced competitive positioning against major players like Invitae and Myriad Genetics in the hereditary cancer testing space
- Technological validation of Fulgent's proprietary platform through partnership with an industry leader
The ability to pair germline testing with Foundation Medicine's somatic testing creates a compelling integrated offering that could drive increased test volumes and revenue per patient. This comprehensive approach aligns with the growing trend toward complete molecular profiling in oncology care pathways.
The February 28, 2025 launch timing provides adequate runway for commercial preparation while allowing early 2025 revenue impact. The partnership structure leveraging Fulgent's technology platform suggests favorable economics, though specific terms weren't disclosed.
This partnership positions Fulgent strategically in the rapidly expanding precision oncology market, estimated to reach
- Growing adoption of comprehensive genomic profiling in standard cancer care, with
15-20% annual growth in test volumes - Increasing demand for integrated somatic and germline testing solutions that provide complete molecular insights
- Strong reimbursement trends for hereditary cancer testing, with major commercial payers expanding coverage
- Rising focus on preventive and family-based genetic screening creating new market opportunities
The partnership leverages complementary strengths - Foundation Medicine's market presence and clinical validation combined with Fulgent's technical expertise and cost-efficient operations. This could drive competitive advantages in test economics and market access.
The launch of two distinct panels (50 vs 154 genes) allows market segmentation and pricing flexibility while establishing Fulgent as a comprehensive player in hereditary cancer diagnostics. Integration with Foundation Medicine's portal enables seamless ordering workflow, reducing barriers to adoption.
FoundationOne Germline is a next-generation sequencing (NGS) test that analyzes 50 genes associated with hereditary cancers. It is suitable for individuals with a personal or family history indicative of hereditary cancers. FoundationOne Germline More is an expanded NGS panel analyzing 154 genes, including well-established cancer-related genes and candidate genes with emerging evidence of association with cancer risk. It is intended for individuals with complex clinical presentations and family histories requiring broader genetic analysis.
“Healthcare providers have many factors to consider when making treatment decisions, and we are always looking to bring additional solutions to the market to provide as much information as possible,” said Annie Murphy, chief commercial officer at Foundation Medicine. “The results from our germline tests can help explain why a patient initially developed cancer and provide insights into potential increased future cancer risks, delivering important new value to the healthcare providers and patients we serve.”
Both tests are powered by Fulgent’s proprietary technology platform and analyze single nucleotide and copy number variations. When combined with Foundation Medicine’s comprehensive genomic profiling (CGP) tests, FoundationOne®CDx, FoundationOne®Liquid CDx, FoundationOne®Heme and FoundationOne®RNA, germline testing supports healthcare providers in building a more comprehensive molecular profile for their patients.
“There is no doubt the time has come to pair germline and somatic testing, and this new partnership brings together two companies that are exceedingly strong in each,” said Brandon Perthuis, chief commercial officer at Fulgent. “We are very excited to bring this offering to oncologists in partnership with Foundation Medicine, and we look forward to a strong collaboration with a mutual goal of advancing patient care.”
Foundation Medicine and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
About Foundation Medicine: Your Essential Partner in Cancer Care
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on LinkedIn and X.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204855154/en/
Media Contact:
Foundation Medicine:
Holly
newsroom@foundationmedicine.com
Source: Foundation Medicine
FAQ
When will Fulgent Genetics (FLGT) launch the new FoundationOne germline tests?
How many genes does FoundationOne Germline More analyze compared to the standard version?
What technology does FLGT use for the new FoundationOne germline tests?
How will the Foundation Medicine partnership affect FLGT's cancer diagnostics offerings?
